Top-Rated StocksTop-RatedNASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $20.07 -0.47 (-2.29%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sutro Biopharma Stock (NASDAQ:STRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$19.86▼$20.4350-Day Range$20.07▼$33.3552-Week Range$7.15▼$43.85Volume124,764 shsAverage Volume281,286 shsMarket Capitalization$332.76 millionP/E RatioN/ADividend YieldN/APrice Target$47.30Consensus RatingBuy Company Overview Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas. With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.AI Generated. May Contain Errors. Read More Sutro Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 508th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSutro Biopharma has a consensus price target of $47.30, representing about 135.7% upside from its current price of $20.07.Amount of Analyst CoverageSutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($8.41) to ($6.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sutro Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.40% of the float of Sutro Biopharma has been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 5.39.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 6.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for STRO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STRO Stock News HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)August 14, 2026 | theglobeandmail.comSTRO stock plummets 15% — what drove the selloff?August 12, 2026 | msn.comLabor Day Warning: The secret that called 1929 is flashing something newIn 1929, a young researcher named Irving Weiss spotted warning signs Wall Street ignored - then watched the Dow crash nearly 13% in a single day, followed by another 12% drop the next. His research became Weiss Ratings, a system The Wall Street Journal ranked number one for investment performance. It also called the Dot-Com Bust, the 2008 crisis, and the 2020 crash. Now the system is flagging a possible shift in the back half of 2026, separating stocks it flags as vulnerable from those positioned to climb.September 4 at 1:00 AM | Weiss Ratings (Ad)Why is Sutro Biopharma Stock Falling On Wednesday?August 12, 2026 | benzinga.comSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 StudyAugust 12, 2026 | globenewswire.comNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsMay 28, 2026 | finance.yahoo.comUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17, 2026 | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $11.57 at the beginning of 2026. Since then, STRO stock has increased by 73.5% and is now trading at $20.07. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.19) by $0.14. The firm earned $9.84 million during the quarter, compared to analysts' expectations of $11.96 million. When did Sutro Biopharma's stock split? Sutro Biopharma's stock reverse split on Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $85 million in an IPO on Thursday, September 27th 2018. The company issued 5,667,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's top institutional shareholders include Merck & Co. Inc. (1.64%), Seven Fleet Capital Management LP (0.96%), Bank of New York Mellon Corp (0.25%) and Wellington Management Group LLP (0.07%). Insiders that own company stock include Jane Chung, Hans-Peter Gerber, David Pauling, Connie Matsui, Gregory K Chow and Nicki Vasquez. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/12/2026Today9/04/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, STRO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STRO CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year Founded2003Price Target and Rating Average Price Target for Sutro Biopharma$47.30 High Price Target$60.00 Low Price Target$27.00 Potential Upside/Downside+135.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($11.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$191.09 million Net Margins-395.25% Pretax Margin-395.46% Return on EquityN/A Return on Assets-88.12% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual Sales$102.48 million Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value($6.23) per share Price / Book-3.22Miscellaneous Outstanding Shares16,580,000Free Float16,283,000Market Cap$332.76 million OptionableOptionable Beta1.48 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:STRO) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredMan Who Called SpaceX Rise Says Elon’s NEW Project is Even BiggerJames Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...Paradigm Press | SponsoredHalf the market is standing on a trapdoorNearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...Behind the Markets | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
